AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Amgen’s Q3 2026 revenue rose 8% year over year to $10.4 billion, while diluted GAAP EPS increased 19% to $7.08 and non-GAAP EPS rose 14% to $6.45. The company forecast full-year 2026 revenue of $38.9 billion–$39.7 billion and non-GAAP EPS of $22.90–$23.70; it also reported significant clinical updates, including positive Phase 3 results for IMDELLTRA in small-cell lung cancer. Free cash flow declined to $3.7 billion from $4.2 billion a year earlier, and several products faced sales declines amid competition and pricing pressures.

Analysis

Read-through: The favorable headline EPS growth overstates the improvement in recurring economics: GAAP benefited from lower acquisition-related amortization and a much smaller impairment/other-expense burden, while non-GAAP operating margin was essentially flat. The better signal is broad product volume growth, but portfolio quality is uneven: newer growth engines are offsetting steep biosimilar erosion in Prolia/XGEVA and price pressure in Enbrel. Repatha’s outcomes analyses and IMDELLTRA’s expanding clinical evidence could strengthen adoption over the next 1–3 months, but neither should be capitalized as durable revenue without prescribing, access, and confirmatory data. MariTide is the largest 6–18 month valuation option: its dosing convenience could differentiate against established obesity therapies, but Phase 3 execution and tolerability—not management’s positioning—will determine whether it changes the earnings trajectory. AZN has collaboration exposure to TEZSPIRE and sunakiment; the release provides no basis to quantify the economics. XNCR and ZLAB are tied to investigational oncology collaborations, not near-term consolidated growth drivers.

Risks and contrarian view: Consensus may focus on top-line breadth and pipeline optionality while underweighting the flat adjusted margin, continued legacy-product price/volume leakage, and cash conversion volatility. Working-capital timing explains some FCF decline, but debt remains a constraint on the flexibility implied by growth and dividends. FDA action on TAVNEOS is a discrete downside catalyst; Medicare pricing pressure and biosimilar substitution are more persistent. No valuation, prior guidance comparison, or post-release price action is supplied, so the print alone does not establish an attractive entry or that guidance is a raise.

Key Decisions for Investors

• Do not chase AMGN solely on GAAP EPS growth. Consider a starter long only on post-print weakness, sizing against a thesis that depends on continued volume growth and stable non-GAAP margin; reassess if management cuts the 2026 outlook or adjusted margin deteriorates further.
• Over the next 1–3 months, monitor product-level volume and net-price trends, especially Enbrel, Prolia/XGEVA, Repatha, and IMDELLTRA, plus FDA developments on TAVNEOS. A renewed acceleration in legacy erosion or an adverse TAVNEOS decision would weaken the long thesis.
• Treat MariTide as pipeline optionality, not current earnings support. Revisit exposure as Phase 3 data and trial timing emerge; materially weaker weight-loss efficacy, tolerability, or persistence versus established therapies would falsify the differentiation case.
• Before adding, verify management’s conference-call commentary on whether guidance changed, the composition of non-GAAP cost growth, working-capital normalization, and capital-return priorities given debt and lower quarterly free cash flow. Without those checks or a favorable entry price, no event-driven trade is warranted.